Dr Rakesh Popat

Dr Rakesh PopatTel: 020 3447 8028
Fax: 020 3447 9911
Email: uclh.uclh.myelomaadminteam@nhs.net

University College Hospital

Myeloma, Blood Diseases (clinical haematology)

Professional background

Rakesh Popat graduated from Guy’s and St. Thomas’ Medical School in London and trained in haematology at St. Bartholomew’s and the Royal London Hospitals.

During this time he completed a PhD thesis focusing on designing scientifically based treatment combinations for multiple myeloma. This included pre-clinical work investigating novel drug combination treatments, and developing them into early phase clinical trials.

He was awarded a fellowship to visit the Dana Farber Cancer Institute in Boston, USA where he gained experience both in their drug discovery laboratory and clinical programs. 

Dr. Popat is a Consultant Haematologist at UCH, Honorary Clinical Senior Lecturer at the UCL Cancer Institute,  a member of the NCRI Myeloma sub-group and currently the North Thames Clinical Research Network Specialitiy Lead for Haematology (Cancer division).

Research interests

The clinical development of new treatments for patients with Haematological cancers.  He leads the early phase clinical trial program for haematological malignancies and is the Principle Investigator of a number of Phase I and II clinical trials at the NIHR/ Wellcome UCH Clinical Research Facility and UCH Macmillan Cancer Centre.


An Alternative Dosing Strategy of lenalidomide for patients with relapsed multiple myeloma. Popat, R, Khan I, Dickson J, Cheesman S, Smith D, D'Sa S, Rabin, N, Yong, K. Br J Haematol

The Histone Deacetylase Inhibitor UCL67022 has potent activity in Multiple Myeloma and Non-Hodgkin’s lymphoma pre-clinical models. Maharaj L, Marson CM, Middleton BJ, Rioja A, Perry J, Oakervee H, Cavenagh J, Joel SP, Popat R. Br J Haematol. 2013 Oct;163(1):135-9.

Schedule dependent cytotoxicity of bortezomib and melphalan in multiple myeloma. Popat R, Maharaj L, Oakervee H, Cavenagh J, Joel S.  Br J Haematol. 2013 Jan;160(1):111-4.

A phase 2 study of SRT501 (resveratrol) with bortezomib for patients with relapsed and or refractory multiple myeloma. Popat R, Plesner T, Davies F, Cook G, Cook M, Elliott P, Jacobson E, Gumbleton T, Oakervee H, Cavenagh J. Br J Haematol. 2013 Mar;160(5):714-7

Bortezomib, low-dose intravenous melphalan, and dexamethasone for patients with relapsed multiple myeloma.  Popat R, Oakervee H, Williams C, Cook M, Craddock C, Basu S, Singer C, Harding S, Foot N, Hallam S, Odeh L, Joel S, and Cavenagh J.  Br J Haematol. 2009 Mar;144(6):887-94.

Bortezomib, doxorubicin, and dexamethasone (PAD) front-line treatment of multiple myeloma: updated results after long-term follow-up. Popat R, Oakervee H.E., Hallam S, Curry N, Odeh L, Foot N,  Esseltine D, Drake M, Morris TC, Cavenagh JD: Br J Haematol 2008 May;141(4):512-6

Bortezomib is effective in primary plasma cell leukemia. D  Finnegan, P Kettle, M Drake, C Matthews, D Alexander, R Popat, J Cavenagh, W Wachsman, C Morris. Leuk Lymphoma. 2006 Aug;47(8):1670-3

Bortezomib for Multiple Myeloma. R Popat, S.P. Joel, H.E. Oakervee, J.D. Cavenagh.  Expert Opinion in Pharmacotherapy. 2006 Jul;7(10):1337-1346

PAD combination therapy (PS-341/bortezomib, doxorubicin and dexamethasone) for previously untreated patients with multiple myeloma. Oakervee HE., Popat R, Curry N, Smith P, Morris C, Drake M, Agrawal S, Stec J, Schenkein D, Esseltine D & Cavenagh, JD. Br J Haematol 2005 129 (6), 755-762.

Bortezomib Combination Therapy for Multiple Myeloma. R Popat, H E Oakervee, J D Cavenagh.  British Journal of Cancer Management 2005 Vol 2, No.2, 17-19.

PAD combination therapy (PS-341/bortezomib, doxorubicin and dexamethasone) for untreated patients with multiple myeloma: A Case Study and Synopsis. R Popat, H E Oakervee, J D Cavenagh. The American Journal Of Oncology Review. 2005, Vol 4, No. 12, 750-756.

GMC/GDC number: 4432920